essence study semaglutide In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly improved liver histologic results at 72 weeks. Full trial results and Research Summary Breaking! Phase 3 ESSENCE trial

The highest dose produced weight loss comparable to liraglutide 3.0 mg, establishing cagrilintide as the first long-acting amylin analog to demonstrate clinically meaningful weight reduction in a randomized trial

Final Thoughts: Staying Ahead of the Curve Deciding to use medical weight loss treatments is an investment in your longevity

For older adults with type 2 diabetes, starting GLP-1 receptor agonists was found to significantly reduce the risk of developing PD compared to dipeptidyl peptidase-4 inhibitors [30]

Use qualified, trained providers, maintain sterile technique, conduct proper patient screening, and follow strict aftercare protocols

That means you start at a lower dose and then gradually increase the dosage every few weeks